Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Credit agrmnt [a]
Appointed director
|
|
TransMedics Group, Inc. (TMDX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Quarterly results |
| 08/01/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/04/2021 |
8-K
| Quarterly results |
| 11/04/2020 |
8-K
| Quarterly results |
| 08/05/2020 |
8-K
| Quarterly results |
| 05/06/2020 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : May 6, 2020 TransMedics Group, Inc. Massachusetts 001-38891 83-2181531 200 Minuteman Road Andover, Massachusetts 01810 552-0900 Registrant's Telephone Number, Including Area Code",
"TransMedics Reports First Quarter 2020 Financial Results Andover, Mass. - May 06, 2020 - TransMedics Group, Inc. , a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended March 31, 2020. “We began 2020 with strong momentum and remain extremely confident in TransMedics' long-term prospects,” said Waleed Hassanein, MD, President and Chief Executive Officer. “We continue to lean forward throughout this COVID-19 pandemic to establish and broaden our technological and clinical service offering to facilitate organ procurement and transplantation using our OCS Technology during and in the post-COVID era. We have also taken extensive measures to preserve cash and mit..." |
|
| 11/06/2019 |
8-K
| Quarterly results |
| 08/07/2019 |
8-K
| Quarterly results |
| 06/11/2019 |
8-K
| Quarterly results |
|
|